抗MDA5阳性临床无肌病性皮肌炎荷兰患者的临床特征与免疫相关蛋白模式
本研究纳入2015年12月至2017年11月诊断为抗MDA5阳性皮肌炎的20例荷兰患者,均为临床无肌病性皮肌炎,诊断时94%存在间质性肺病,45%表现为快速进展性间质性肺病,诊断后4个月内死亡率为35%,呼吸衰竭为主要死因。对16例患者和15名健康对照的180种免疫相关标志物检测显示,快速进展性间质性肺病患者炎症血清谱与健康对照明显不同,IFN、IL1、IL10和IL18信号通路调控存在差异,这些标志物尚待进一步验证后方可用于临床。
要点
- 抗MDA5阳性临床无肌病性皮肌炎患者诊断时94%存在间质性肺病,45%为快速进展性间质性肺病。
- 诊断后4个月内死亡率为35%,呼吸衰竭为主要死因。
- 快速进展性间质性肺病患者炎症血清谱与健康对照明显不同,IFN、IL1、IL10和IL18信号通路调控存在差异。
核心结论
- 在荷兰抗MDA5阳性临床无肌病性皮肌炎队列中,三分之一患者诊断后不久死于快速进展性间质性肺病,凸显该病严重性。
- 研究发现快速进展性间质性肺病 vs 无快速进展性间质性肺病皮肌炎及健康对照间存在若干可能差异调控的通路,这些标志物尚待进一步验证后方可用于临床。
研究设计与样本
- 纳入2015年12月至2017年11月诊断为抗MDA5阳性皮肌炎的患者,从病历中回顾性采集临床数据。
- 采用基于邻近延伸分析的技术检测16例患者和15名健康对照血清中的180种免疫相关标志物。
主要发现
- 共纳入20例患者,均为临床无肌病性皮肌炎,从症状出现至诊断的中位时间为4个月。
- 诊断时94%的患者存在间质性肺病,45%表现为快速进展性间质性肺病。
- 诊断后4个月内死亡率为35%,呼吸衰竭为主要死因。
- 无监督分析显示,快速进展性间质性肺病患者炎症血清谱与健康对照明显不同。
- 与健康对照相比,抗MDA5阳性患者中IFN、IL1、IL10和IL18信号通路调控存在差异。
局限性
- 这些标志物尚待进一步验证后方可用于临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The presence of melanoma differentiation-associated protein 5 (MDA5) antibodies in patients with DM is associated with the development of a rapidly progressive interstitial lung disease (RPILD), unresponsive to conventional treatment. We characterize patients and provide more insight into potential biomarkers to identify patients with RPILD. METHODS: Patients diagnosed with anti-MDA5 positive DM between December 2015 and November 2017 were included in this study. Clinical data were retrospectively retrieved from medical records. A total of 180 immune-related markers were measured in sera of 16 patients and 15 healthy controls using proximity extension assay-based technology. RESULTS: Twenty patients were included, with a median time from symptoms till diagnosis of 4 months. All patients had clinically amyopathic DM. Interstitial lung disease (ILD) was present at diagnosis in 94% of the patients, 45% presented with RPILD. The mortality rate was 35% within 4 months after diagnosis and respiratory failure was the main cause of death in these patients. Furthermore, unsupervised analysis revealed that patients with RPILD show clearly different inflammatory serum profiles than healthy controls. In addition, in comparison to healthy controls, the IFN, IL1, IL10 and IL18 signalling pathways are different regulated in anti-MDA5 positive patients. CONCLUSION: In this Dutch anti-MDA5 positive clinically amyopathic DM (CADM) cohort, one-third of the patients died due to RPILD soon after diagnosis, which underlines the severity of this disease. In addition, we have found several possible pathways that are differentially regulated in RPILD vs no RPILD DM and healthy controls. These markers await further validation before clinical use.
引用
- Hensgens MPM, Delemarre EM, Drylewicz J, et al. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. Rheumatology (Oxford). 2022. PMID: 35048953. doi:10.1093/rheumatology/keac030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。